Summary:
- This article analyzes the Pfizer COVID-19 vaccine trial data and challenges the reported 95% vaccine effectiveness.
- The analysis suggests that the actual vaccine effectiveness was much lower, around 19-29%, due to issues with the trial design and data reporting.
- The article raises concerns about the transparency and accuracy of the vaccine trial results, which have significant implications for public health policies and decisions.